Episode 17: Appen’s acquisition, Advance NanoTek, Clinuval Pharmaceuticals and more!

This week, we dissect Appen’s latest acquisition and touch on the ethics of AI.

We look to why shares in Envirosuite have surged higher, and ask whether the phenomenal gains from Clinuval Pharmaceuticals and Advance NanoTek can continue.

Plus Matt updates us on his recent meeting with the PushPay team.

For more great content, please visit us at www.strawman.comwww.mattjoass.com & www.ethicalequities.com.au

Email us at [email protected]

And find us on Twitter @sage_simian @mattjoass @claudedwalker

Return to the Strawman Platform here

Strawman is Australia’s premier online investment club. Join for free to access independent & actionable recommendations from proven private investors.

This Service provides general financial advice only, and has not taken your personal circumstances into account. Strawman Pty Ltd operates under AFSL 501223 . For more information please see our Terms of use. Please remember that share market investments can go up and down and that past performance is not necessarily indicative of future returns. Strawman Pty Ltd does not guarantee the performance of, or returns on any investment.

© 2019 Strawman Pty Ltd. All rights reserved.

| Privacy Policy | Terms of Service |

ACN: 610 908 211 | Australian Financial Services Licence (AFSL): 501223

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to our
Capitalize on low hanging fruit to identify a ballpark value.